TREATMENT EFFECTIVENESS ANALYSIS OF OUTPATIENTS WITH ARTERIAL HYPERTENSION PLUS CORONARY HEART DISEASE IN UKRAINE

The analysis of quality of the survey and using of drug therapy in patients with coronary heart disease with concomitant hypertension in outpatient clinics of large cities in Ukraine was conducted in the PRESTIGE study. Methods for evaluation of patients included: ECG at rest (98.3%), echocardiography (83.7%), ambulatory ECG monitoring (47.8%), test with dosed physical load (24.4%), ambulatory blood pressure monitoring (28.7%), coronary angiography (20.0%), determining of microalbuminuria and glomerular filtration rate (21.9 and 13.8% respectively). Analysis of medical prescriptions in the PRESTIGE study suggests that the choice of the main groups of drugs and drugs used in clinical practice is very close to international standards. The frequency of use of antithrombotic and lipid-lowering (statin) agents, BB and ACE inhibitors (medicines that improve the prognosis of patients with coronary artery disease) are comparable with data from recent international registers. However, the effectiveness of therapy in the light of generally accepted criteria remains critically insufficient. Despite treatment, the target cholesterol was achieved in only 23% of patients, and target levels of blood pressure (130/85 mm Hg) in only 12.5% of patients. In 63.4% of patients, including those receiving BB, heart rate remained more than 70 bmp. Referai of patients with CHD to myocardial revascularization should be recognized as passive tactic and the number of interventions performed is inadequate. Factors that could enhance the efficacy of therapy would be the application of adequate doses of drugs, monitoring and control for achieving of target levels of key indicators (LDL cholesterol, blood pressure, heart rate), as well as increasing patients' adherence to treatment.

прогноз больных ИБС, эффективность терапии, амбулаторное лечение, артериальная гипертензия, prognosis of patients with coronary artery disease, the effectiveness of treatment, outpatient treatment, arterial hypertension

1. Аронов Д.М. Терапевтический каскад статинов. // Consilium medicum, 2003 (экстравыпуск), с 7-10.

2. Горбась I.M. Ішемічна хвороба серця: епідеміологія і статистика. // Здоров»я України. - 2009,- березень ; 34-35.

3. М.И. Путай, А.Ф. Лысенко. - Анализ медикаментозной терапии ишемической болезни сердца в Украине: результаты исследования PULSAR-Украинский кардиологический журнал. - № 3-2010. - стр. 36-43.

4. Медикаментозне лікування стабільної стенокардії. - Методичні рекомендації Робочої групи з проблем атеросклерозу та хронічних форм ІХС Асоціації кардіологів України. - 2010 р.

5. Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування. - Методичні рекомендації Асоціації кардіологів України під редакцією В.М. Коваленка, М.І. Лутая, Ю.М. Сіренка - 2010 р.

6. Чазов Е.И., Беленков Ю.Н. - Рациональная фармакотерапия сердечно-сосудистых заболеваний. Руководство для практикующих врачей -М.: Литтерра. - 2004. - т. 4

7. Alberts M.J. et al. -Three-year follow-up and event rates in the international Reduction of atherothrombosis for Continued Health Registry -Eur Heart J - 2009; 30: 2318-26.

8. Cacoub P.P. et al. - Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. - Atherosclerosis. - 2009; 204(2): e86-92

9. Cannon C.P., Braunwald E., McCabe C.H. et al. - Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. - N Engl J. Med. - 2004 - 350

10. DeBacker G., Ambrosioni E., Borch-Johnsen et al. - European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice - Eur Heart J. 2003, 24: 1601-1610.

11. Deedwania P., Barter P., Carmena R. et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. - Lancet - 2006, 368: 919-928.

12. ESC Guidelines for the Management of Stable Angina Pectoris - Eur Heart J. - 2006, 27: 1341-1381.

13. ESC Guidelines on myocardial revascularization.- European Heart Journal (2010) 31-l-2555doi:10.1093. - eurheartj. - ehq277.

14. Fox K., Ford I., Steg P.G., et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. - Eur Heart J. Advance Access. - August 31- 2009. - P. 1-9.

15. Freemanlle N., Cleland J., Young P. et al. - Beta blockade after myocardial infarction: systematic review and meta regression analysis. - BMJ. 1999; 318: 1730-1737.

16. Heart Protection Study Collaborative Group. - MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002; 360: 7-22.

17. Krempf M. et al. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (From the REduction of Atherothrombosis for Continued Health [REACH] Registry). - Am J. Cardiol -2010; 105(5): 667-671.

18. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis (REVERSAL) trial. - JAMA. - 2004, 211: 1071-80.

19. Swedberg K. - Pure heart rate reduction: further perspectives in heart failure - Eur Heart J. Suppl. October. - 2010. - 12,. - p. F20-F24.

20. Tardif J.-C., Ponikowski P., Kahan Th. - Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial (ASSOCIATE study). - / Eur Heart J. Advance Access. January 9. 2009 P. 1-9.

21. The Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). - Lancet. - 1994. - 344: 1383-1389.